Scholar Rock (NASDAQ:SRRK) Price Target Raised to $50.00 at HC Wainwright

Scholar Rock (NASDAQ:SRRK) had its price objective raised by HC Wainwright from $40.00 to $50.00 in a research note released on Tuesday morning, MarketBeat Ratings reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Scholar Rock’s FY2026 earnings at ($1.57) EPS, FY2027 earnings at ($0.78) EPS and FY2028 earnings at $0.18 EPS.

Several other equities research analysts have also recently issued reports on the company. JPMorgan Chase & Co. raised their price objective on Scholar Rock from $18.00 to $31.00 and gave the stock an “overweight” rating in a report on Monday, October 14th. Truist Financial lifted their price target on Scholar Rock from $36.00 to $45.00 and gave the company a “buy” rating in a report on Monday. Wedbush increased their price objective on shares of Scholar Rock from $40.00 to $47.00 and gave the stock an “outperform” rating in a report on Monday. Piper Sandler boosted their target price on shares of Scholar Rock from $28.00 to $42.00 and gave the company an “overweight” rating in a report on Tuesday, October 15th. Finally, BMO Capital Markets increased their price target on shares of Scholar Rock from $34.00 to $38.00 and gave the stock an “outperform” rating in a research note on Friday, October 11th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Scholar Rock has a consensus rating of “Buy” and a consensus target price of $40.43.

Scholar Rock Stock Up 2.9 %

Shares of NASDAQ SRRK opened at $38.15 on Tuesday. The firm has a market cap of $3.57 billion, a P/E ratio of -16.23 and a beta of 0.47. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. Scholar Rock has a 1 year low of $6.76 and a 1 year high of $43.38. The firm’s 50 day moving average price is $24.29 and its 200 day moving average price is $14.54.

Insider Activity

In other Scholar Rock news, major shareholder Public Equities L.P. Invus sold 409,433 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $38.49, for a total value of $15,759,076.17. Following the completion of the sale, the insider now owns 10,850,005 shares of the company’s stock, valued at $417,616,692.45. This trade represents a 3.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Tracey Sacco sold 30,000 shares of the business’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $25.62, for a total transaction of $768,600.00. Following the transaction, the insider now directly owns 49,285 shares in the company, valued at approximately $1,262,681.70. The trade was a 37.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,823,322 shares of company stock valued at $56,411,627. Company insiders own 19.20% of the company’s stock.

Institutional Investors Weigh In On Scholar Rock

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC grew its stake in shares of Scholar Rock by 95.5% during the first quarter. Jane Street Group LLC now owns 244,318 shares of the company’s stock valued at $4,339,000 after acquiring an additional 119,363 shares in the last quarter. Clearbridge Investments LLC acquired a new stake in Scholar Rock during the 2nd quarter valued at approximately $6,223,000. Kennedy Capital Management LLC purchased a new stake in Scholar Rock during the 1st quarter worth approximately $4,900,000. Vanguard Group Inc. raised its position in shares of Scholar Rock by 4.0% in the 1st quarter. Vanguard Group Inc. now owns 2,969,534 shares of the company’s stock valued at $52,739,000 after purchasing an additional 114,550 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in shares of Scholar Rock during the 3rd quarter valued at approximately $1,093,000. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.